{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:36:41Z","timestamp":1792676201668,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Parvovirus B19 (B19V) has been found in asymptomatic blood donors. This prospective study tested linked blood donor\u2013recipient samples from patients transfused at the National Institutes of Health (NIH) and affiliated hospitals for the presence of B19V DNA and anti-B19 immunoglobulin G (IgG) antibodies to assess the risk of B19V transmission by transfusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Post-transfusion recipient plasma samples collected during 2002\u20132020 were tested for B19V DNA at 1, 2, 4, and\/or 8\u202fweeks by nested polymerase chain reaction (PCR), and for anti-B19 IgG at 12 and \u226524\u202fweeks by enzyme immunoassay (EIA). To confirm B19V DNA-positive recipients, pre-transfusion and linked donation samples were tested for B19V DNA, anti-B19 IgG, and\/or IgM. Tested samples included 1,352 subjects tested for DNA and anti-B19V IgG, or both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No new transfusion-transmitted B19V infections were identified. Only one confirmed transfusion-transmitted infection (TTI) was identified overall. A total of 19 of 1,314 subjects tested for B19V DNA (1.4%, 95% confidence interval [CI]: 0.014 [0.009, 0.021]) had a positive result in their post-transfusion sample. A total of 876 of 1,290 tested subjects were positive for anti-B19V IgG antibody (68%, 95% CI: 0.679 [0.65, 0.70]). Antibody detection fluctuated among some recipients from 12 to 24\u202fweeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The B19V DNA-positive rate in recipients was very low. All B19V DNA-positive recipients had pre-existing antibodies, indicating prior exposure. Although these data may not provide enough evidence to consider revising current B19V testing strategies, other pooled plasma testing data from around the world suggest that more widespread B19V monitoring of blood products could be indicated to prevent B19V infection in immunosuppressed or otherwise susceptible recipients (e.g., individuals with chronic hematological diseases, pregnant women less than 20 weeks gestation).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1819397","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:46:09Z","timestamp":1778564769000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular and serologic analysis of linked blood donor and recipient samples to rule out transfusion-transmitted parvovirus B19 infection"],"prefix":"10.3389","volume":"14","author":[{"given":"Maureen J.","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Transfusion Medicine, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Virata","sequence":"additional","affiliation":[{"name":"Plasma Derivatives Branch 2, Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Proteins, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Yan","sequence":"additional","affiliation":[{"name":"Plasma Derivatives Branch 2, Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Proteins, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Plasma Derivatives Branch 2, Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Proteins, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreya","family":"Tarafdar","sequence":"additional","affiliation":[{"name":"Plasma Derivatives Branch 2, Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Proteins, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Plasma Derivatives Branch 2, Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Proteins, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration","place":["Silver Spring, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, National Institutes of Health Clinical Center","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"ref1","first-page":"D776","article-title":"Virus taxonomy: the database of the International Committee on Taxonomy of Viruses","volume-title":"Nucleic Acids Res","author":"Black","year":"2026"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.virol.2017.08.011","article-title":"Parvovirus B19 integration into human CD36+ erythroid progenitor cells","volume":"511","author":"Janovitz","year":"2017","journal-title":"Virology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1574-695X.2011.00819.x","article-title":"Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions","volume":"62","author":"Slavov","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref4","volume-title":"Risks Posed by Reported Increased Circulation of human Parvovirus B19 in the EU\/EEA","author":"Ancona","year":"2024"},{"key":"ref5","volume-title":"Human Parvovirus B19","year":"2024"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1182\/blood-2018-11-833996","article-title":"Prevention of transfusion-transmitted infections","volume":"133","author":"Busch","year":"2019","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1182\/blood-2008-07-077370","article-title":"The hazards of blood transfusion in historical perspective","volume":"112","author":"Alter","year":"2008","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000445195","article-title":"Parvovirus B19 passive transmission by transfusion of intercept\u00ae blood system-treated platelet concentrate","volume":"43","author":"Gowland","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000548745","article-title":"Parvovirus B19 infection after transfusion of a pathogen-reduced platelet concentrate: a case report","volume":"53","author":"Solari","year":"2025","journal-title":"Transfus Med Hemother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4103\/ajts.ajts_185_20","article-title":"Molecular and serological markers of human parvovirus B19 infection in blood donors: a systematic review and meta-analysis","volume":"15","author":"Farahmand","year":"2021","journal-title":"Asian J Transfusi Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/blood-2009-06-225706","article-title":"A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion","volume":"114","author":"Kleinman","year":"2009","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/j.1537-2995.2010.02591.x","article-title":"Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples","volume":"50","author":"Yu","year":"2010","journal-title":"Transfusion"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/trf.14965","article-title":"Modeling the parvovirus B19 blood safety risk in Australia","volume":"59","author":"Styles","year":"2019","journal-title":"Transfusion"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"150820","DOI":"10.1016\/j.tmrv.2024.150820","article-title":"Natural history studies, a natural next step to study emerging transfusion-transmitted infections","volume":"38","author":"Miller","year":"2024","journal-title":"Transfus Med Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1128\/jvi.58.3.921-936.1986","article-title":"Nucleotide sequence and genome organization of parvovirus B19 isolated from the serum of a child during aplastic crisis","volume":"58","author":"Shade","year":"1986","journal-title":"J Virol"},{"key":"ref16","volume-title":"Parvovirus B19 Antibodies, IgG and IgM, Serum","year":"2026"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/tme.12893","article-title":"Detection frequencies and viral load distribution of parvovirus B19 DNA in blood and plasma donations in England","volume":"32","author":"Williams","year":"2022","journal-title":"Transfus Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e70380","DOI":"10.1002\/jmv.70380","article-title":"Parvovirus B19 rebound","volume":"97","author":"Ranno","year":"2025","journal-title":"J Med Virol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12884-025-07575-3","article-title":"Impact of the COVID-19 pandemic on parvovirus B19 infection rates in pregnancy: is there a post-pandemic epidemic?","volume":"25","author":"Haberl","year":"2025","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/v17040523","article-title":"Compelling increase in parvovirus B19 infections: analysis of molecular diagnostic trends (2019\u20132024)","volume":"17","author":"Liotti","year":"2025","journal-title":"Viruses"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e016658","DOI":"10.1136\/bmjgh-2024-016658","article-title":"Outbreak of parvovirus B19 disease in France: urgent need in public health for relevant tools to track epidemics in real-time","volume":"10","author":"Migueres","year":"2025","journal-title":"BMJ Glob Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1111\/trf.18032","article-title":"Parvovirus B19 rebound outbreak 2024 and implications for blood- and plasma-product safety","volume":"64","author":"Farcet","year":"2024","journal-title":"Transfusion"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"105873","DOI":"10.1016\/j.jcv.2025.105873","article-title":"Assessing B19V epidemiology and viremia dynamics in plasma donors: a comprehensive analysis","volume":"181","author":"W\u00e4lti","year":"2025","journal-title":"J Clin Virol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.15585\/mmwr.mm7347a2","article-title":"Detection of increased activity of human parvovirus B19 using commercial laboratory testing of clinical samples and source plasma donor pools \u2014 United States, 2024","volume":"72","author":"Alfego","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref25","volume-title":"Increase in Human Parvovirus B19 Activity in the United States","year":"2024"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/vox.13616","article-title":"Decreasing parvovirus B19 and hepatitis a nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID-19 restriction in March 2020","volume":"119","author":"Drews","year":"2024","journal-title":"Vox Sang"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/v16091352","article-title":"Reassessing the risk of severe parvovirus B19 infection in the immunocompetent population: a call for vigilance in the wake of resurgence","volume":"16","author":"Ceccarelli","year":"2024","journal-title":"Viruses"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"105798","DOI":"10.1016\/j.jcv.2025.105798","article-title":"Insights into the clinical and molecular epidemiology of an infections outbreak of human parvovirus B19 in France, 2023-2024","volume":"178","author":"Creuzet","year":"2025","journal-title":"J Clin Virol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"106409","DOI":"10.1016\/j.jinf.2025.106409","article-title":"Virological characterization of parvovirus B19 isolated during the atypical 2023-2024 outbreak in France","volume":"90","author":"Veyrenche","year":"2025","journal-title":"J Infect"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1819397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:46:11Z","timestamp":1778564771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1819397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":29,"alternative-id":["10.3389\/fpubh.2026.1819397"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1819397","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1819397"}}